Phillip A. Dennis

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.4K citations · Full text

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

John Brognard, Amy S. Clark, Yucheng Ni et al. · PubMed · 2001 · 892 citations

Chemoprevention Strategy, Immunology, Cell Death +22

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

Kristin J. Lastwika, Willie Wilson, Qing Kay Li et al. · Cancer Research · 2015 · 764 citations

Immunology, Immune Regulation, Immunoediting +20

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

Amy S. Clark, Kip A. West, Samantha A. Streicher et al. · PubMed · 2002 · 591 citations

Breast Oncology, Chemoprevention Strategy, Apoptosis +22